METASTATIC ESOPHAGEAL ADENOCARCINOMA
Clinical trials for METASTATIC ESOPHAGEAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC ESOPHAGEAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC ESOPHAGEAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising combo targets Hard-to-Treat esophageal cancer
Disease control OngoingThis study tests whether adding the drug cixutumumab to standard chemotherapy (paclitaxel) can help people with advanced esophageal or stomach-junction cancer live longer without their cancer growing. About 94 adults whose cancer has spread and who have already tried one treatmen…
Matched conditions: METASTATIC ESOPHAGEAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 06:00 UTC
-
Experimental combo targets Hard-to-Treat esophageal cancer
Disease control OngoingThis early-stage trial tested a drug called adavosertib together with radiation therapy for people with advanced esophageal or stomach cancer that cannot be surgically removed. The goal was to find the safest dose and see how well the combination works. Only 4 people took part, s…
Matched conditions: METASTATIC ESOPHAGEAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Radiation plus chemotherapy may boost survival in stomach and esophageal cancer
Disease control OngoingThis phase III trial is testing whether adding radiotherapy to standard chemotherapy improves survival in patients with HER2 negative esophageal or gastric cancer that has spread to a few other spots in the body (oligometastatic). About 314 participants will receive either chemot…
Matched conditions: METASTATIC ESOPHAGEAL ADENOCARCINOMA
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New Immune-Cell cocktail takes on tough gut cancers
Disease control OngoingThis phase 2 trial is testing a five-drug combination for people with advanced esophageal, stomach, or gastroesophageal junction cancer that has worsened after initial treatment. The combination includes immune cells from healthy donors, two immunotherapy drugs, and two standard …
Matched conditions: METASTATIC ESOPHAGEAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug combo targets Hard-to-Treat esophageal cancer
Disease control OngoingThis study tests a combination of two drugs, abemaciclib and ramucirumab, in people with advanced esophageal or gastroesophageal junction cancer that has spread. The goal is to see if this treatment is safe and can help control tumor growth. About 8 participants are enrolled, and…
Matched conditions: METASTATIC ESOPHAGEAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Baylor Research Institute • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC